News for Addex Therapeutics Ltd (ADXN)

Press Release

Ad Hoc Announcement Pursuant to Art. 53 LR

Trading of Addex Therapeutics (ADXN) shares has recommenced after a brief pause. Investors are now able to engage with this company's market activities once aga

Trading for Addex Therapeutics (ADXN) Ltd ”“ ADR has been temporarily suspended due to a volatility trading pause. This halt is intended to address heightened

Cash Balance: CHF2.8 million as of March 31, 2025.Cash Runway: Expected to last through mid-2026.Continuing R&D Expenses: CHF0.1 million, primarily related to

Jun 19, 2025 / 02:00PM GMTTim Dyer - Addex Therapeutics Ltd - Chief Executive Officer, Co-Founder, Member of the Executive Management, Director Hello, everyone.

**media[659085]**

**media[657944]**

Addex Therapeutics (ADXN) has revealed promising findings regarding the anti-tussive effectiveness of its innovative gamma-aminobutyric acid sub-type B receptor

**media[647382]**

**media[646294]**

**media[643887]**

Addex Therapeutics, known by its ticker ADXN, has entered into a strategic partnership with Sinntaxis AB. This collaboration focuses on an exclusive license con

**media[609719]**

Series A Financing: USD65 million raised for Neurosterix, led by Perceptive Advisors.Cash Received: CHF5 million in cash from the Neurosterix transaction.Equit

Addex Therapeutics Ltd (NASDAQ:ADXN) Q4 2024 Earnings Conference Call April 25, 2025 10:00 AM ETCompany ParticipantsTim Dyer - Co-Founder, Board Director...

**media[605223]**

**media[603870]**

Addex Therapeutics (ADXN) disclosed that it has reacquired all development and commercialization rights to ADX71149 after the termination of its collaboration w